A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation
A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation
Assessment of efficacy and safety UK-390,957.
Inclusion Criteria:
Exclusion Criteria:
Montréal, Quebec, Canada
Bodø, Norway
Balcali, Adana, Turkey (Türkiye)